1. FDA. Xarelto (rivaroxaban). 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022406s028lbl.pdf
2. Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C, Gourmelin Y, Rohde G, Martinoli JL. Laboratory assessment of rivaroxaban: a review. Thrombosis Journal. 2013; 11(11):1-7.
3. Foster A dan Dasgupta D. Oral Anticoagulant Guideline for prescribing, monitoring and management. NHS, 2016. https://www.sps.nhs.uk/wp-content/uploads/2018/02/oral-anticoagulant-oral-guidelines-for-prescribing-monitoring-and-management-v41-2s1.4d-and-2s1.5v-and-5s1.1.d.pdf
4. MIMS. Rivaroxaban. 2020. https://www.mims.com/indonesia/drug/info/rivaroxaban?mtype=generic
5. Trujillo T dan Dobesh PP. Clinical use of rivaroxaban: pharmacokinetic and pharmacodynamic rationale for dosing regimens in different indications. Drugs. 2014; 74(14):1597-1603.
11. National Center for Biotechnology Information. PubChem Compound Summary for CID 9875401, Rivaroxaban. PubChem, 2023 https://pubchem.ncbi.nlm.nih.gov/compound/Rivaroxaban.